MHC-I-driven antitumor immunity counterbalances low absorbed doses of radiopharmaceutical therapy
The study shows that assessing MHC-I expression in tumors could help predict treatment outcomes and guide personalized therapy strategies. Go to this publication at the JRC Publications Repository